Decoding the Pathophysiology and the Genetics of Multiple Myeloma to Identify New Therapeutic Targets
- 1 October 2013
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 40 (5) , 537-548
Abstract
No abstract availableKeywords
This publication has 99 references indexed in Scilit:
- Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomideLeukemia, 2012
- Inhibition of Tumor Cells Interacting with Stromal Cells by Xanthones Isolated from a Costa Rican Penicillium sp.Journal of Natural Products, 2012
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011
- First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialThe Lancet, 2010
- Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic TargetCancer Cell, 2009
- DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their SurvivalCell, 2009
- IRF4 addiction in multiple myelomaNature, 2008
- AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center MalignanciesCancer Cell, 2008
- Widespread microRNA repression by Myc contributes to tumorigenesisNature Genetics, 2007
- Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple MyelomaCancer Cell, 2007